MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
ARCA biopharma ROE Ratio 2011-2026 | ABIO
Annual ROE Ratio ARCA biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.34 | -21.9 | -14.42 | -23.82 | -37.85 | -20.93 | -72.04 | -131.48 | -179.79 | -74.18 | -30.06 | -65.73 | -44.54 | -148.61 | -93.58 | -124.35 | -123.29 | 50.9 | 71.08 | 91.24 | 215.19 | 82.55 | 100.87 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 215.19 | -179.79 | -26.83 |
Quarterly ROE Ratio ARCA biopharma
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.67 | -27.49 | 55.48 | 56.91 | 62.67 | 59.73 | 64.34 | -16.18 | -13.78 | -13.66 | -15.37 | -18.6 | -22.1 | -30.4 | -33.27 | -34.17 | -33.56 | -33.46 | -29.41 | -32.53 | -37.33 | -42.42 | -53.33 | -58.43 | -63.52 | -72.1 | -83.31 | -91.89 | -100.46 | -116.63 | -133.36 | -288.63 | -443.89 | -477.14 | -508.09 | -402.23 | -222.28 | -252.34 | -208.31 | -164.28 | -90.19 | -155.92 | -191.58 | -227.25 | -197.18 | -241.72 | -220.53 | -199.33 | -133.61 | -282.21 | -386.28 | -490.36 | -445.82 | -539.4 | -484.37 | -429.35 | -280.74 | -93.58 | -93.58 | -93.58 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 64.34 | -539.4 | -152.95 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-528.29 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-32.54 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
-55.55 | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
437.8 | - | -13.47 % | $ 169 M | France |
 |
Alpine Immune Sciences
ALPN
|
-9.81 | - | - | $ 2.17 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
332.81 | - | -14.27 % | $ 1.7 M |  Singapore |
 |
AstraZeneca PLC
AZN
|
21.0 | - | - | $ 96.9 B |  Britain |
 |
CureVac N.V.
CVAC
|
23.28 | - | - | $ 867 M | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-380.03 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
30.52 | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
-1.17 | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
3750.6 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-55.98 | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
-183.26 | - | -34.95 % | $ 21.5 M | Germany |
 |
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 49.71 | -1.04 % | $ 4.47 B |  Schweiz |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.4 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-948.23 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-49.08 | $ 30.46 | 1.65 % | $ 2.02 B | USA |
 |
Generation Bio Co.
GBIO
|
-152.74 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
575.45 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
|
Enlivex Therapeutics Ltd.
ENLV
|
63.85 | $ 0.68 | -4.74 % | $ 31.1 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
43.82 | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-169.75 | - | - | $ 384 M | Britain |
 |
Esperion Therapeutics
ESPR
|
7.51 | $ 3.16 | 0.16 % | $ 657 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-44.16 | - | - | $ 3.37 B | China |
 |
Eton Pharmaceuticals
ETON
|
-17.59 | $ 31.27 | -2.63 % | $ 841 M | USA |
 |
Exelixis
EXEL
|
36.21 | $ 53.09 | -0.78 % | $ 14.4 B | USA |
 |
Anika Therapeutics
ANIK
|
-7.58 | $ 14.82 | 0.65 % | $ 213 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 2.91 | 2.11 % | $ 4.79 M | Israel |
|
Forte Biosciences
FBRX
|
-113.75 | $ 17.7 | 1.72 % | $ 229 M | USA |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |